Function description Tackling immunotherapy resistance
The Netherlands Cancer Institute (NKI) Located in Amsterdam, NKI is the only comprehensive cancer center in The Netherlands. It is a well-organized and dynamic institute accommodating over 50 research groups and many advanced core facilities. It is an internationally renowned center dedicated to fundamental, translational and clinical cancer research.
Project information Tumor heterogeneity, immune dysfunction and therapy resistance are among the most substantial challenges that limit durable benefit of cancer (immuno)therapies. Using powerful function-based genomics, we screen for novel therapeutic targets to tackle those clinical problems. In this way we develop new concepts for rational combination treatments, which target both tumor and immune cells, thereby simultaneously eliminating the patient’s tumor and harnessing its immune system. This has already culminated in discoveries that we aim to translate to the benefit of the patient. For this position, we seek a bioinformatician who will collaborate with wet lab PhD students and postdocs on genetic screen analysis, clinical data analysis and related bioinformatic questions. Furthermore, you will be responsible for building and maintaining genomic analysis pipelines, using the latest best practices.
Job requirements Your profile: an ambitious bioinformatician.
We are seeking an enthusiastic and ambitious bioinformatician with a Master degree and a strong interest in cancer biology, (functional) oncogenomics and (immuno)therapy resistance. A solid understanding of basic statistics for bioinformatics is required. Proficiency in English and good communicative skills are also important requirements, as is a team player mentality.
Compensation The vacancy is available immediately. You will be employed for a period of 1 year with the possibility to extend. The gross salary per month is € 2.882 to € 4.227 according to the salary scale FWG 55, and depends on previous experience. The terms of employment will be in accordance with the CAO Hospitals.
In addition you will receive a fixed end-of-year bonus in December (8,33%) and in May you will receive 8,33% holiday pay. For more information in regard to the secondary conditions please visit our website: https://www.nki.nl/careers-study/how-to-apply/
Contact information For further information please contact prof. Daniel Peeper (Division of Molecular Oncology and Immunology). E-mail: email@example.com.
Boshuizen et al., Reversal of pre-existing NGFR-driven tumor and immune therapy resistance, Nature Comm 2020
Boshuizen et al., Rational Cancer Treatment Combinations: An Urgent Clinical Need, Mol Cell 2020
Vredevoogd et al., Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold, Cell 2019
Boshuizen et al., Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Med. 2018
Kong et al., Cancer drug addiction is relayed by an ERK2-dependent phenotype switch, Nature 2017
The NKI values diversity and is committed to creating an inclusive work environment that stimulates the best in each individual. Applications of all individuals are welcomed regardless of age, ancestry, religion, disability, distance from the labor market, sexual orientation or gender identity.